Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perfadex is a low-potassium dextran (LPD) preservation solution specifically designed for the flushing, cold static storage, and transportation of isolated donor lungs prior to transplantation. Developed and marketed by XVIVO (and previously by Vitrolife and Medisan), the solution contains dextran 40 as its primary active component. Dextran 40 acts as a colloid to maintain oncotic pressure and prevent tissue edema, while also coating the vascular endothelium to inhibit the activation and adhesion of leukocytes and thrombocytes. This mechanism protects the lung tissue from post-ischemic reperfusion injury. The 'Plus' version is a ready-to-use formulation that is pre-buffered with THAM (tris-hydroxymethyl aminomethane) and supplemented with calcium ions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Perfadex.